A new study on mice published in Nature Neuroscience finds that fingolimod (Novartis brand name Gilenya) a first-in-class sphingosine-1-phosphate-receptor modulator currently used in treating persons with severe relapsing remitting MS, may also have therapeutic value in treating Post Traumatic Stress Disorder (PTSD). The Nature Neuroscience study is titled…
Gilenya
Recommended Posts
- Certain diets may support thinking skills in people with MS, review finds
- How functional dentistry can help to reduce immune and toxic stress
- Study connects lower levels of rare gut bacterium to higher MS risk
- Childhood trauma may affect treatment adherence in MS patients
- Like the spoon theory, the fork theory can also help explain MS